Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain

Journal of Neuroscience

Volumn 30, Issue 8, 2010, Pages 3146-3155

  Shioda, Norifumi ^a   Yamamoto, Yui ^a   Watanabe, Masahiko ^b   Binas, Bert ^c   Owada, Yuji ^d   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c Hanyang University   (South Korea)

^d YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; DOPAMINE 2 RECEPTOR; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 3; HALOPERIDOL; MITOGEN ACTIVATED PROTEIN KINASE; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEPTH STIMULATION; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DEPOLARIZATION; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INTERNEURON; MOUSE; NEUROBLASTOMA CELL; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ACETYLCHOLINE; ANIMALS; BRAIN CHEMISTRY; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CATALEPSY; CELL LINE, TUMOR; DOPAMINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FATTY ACID-BINDING PROTEINS; GLUTAMIC ACID; HALOPERIDOL; HUMANS; IMMUNOHISTOCHEMISTRY; INTERNEURONS; LIGANDS; METHAMPHETAMINE; MICE; MICE, KNOCKOUT; NEOSTRIATUM; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION;

EID: 77649085143     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4140-09.2010     Document Type: Article

References (66)

1. Aosaki T, Tsubokawa H, Ishida A, Watanabe K, Graybiel AM, Kimura M (1994) Responses of tonically active neurons in the primate's striatum undergo systematic changes during behavioral sensorimotor conditioning. J Neurosci 14:3969-3984.
2. Arai Y, Funatsu N, Numayama-Tsuruta K, Nomura T, Nakamura S, OsumiN (2005) Role of Fabp7, a downstream gene of Pax6, in the maintenance of neuroepithelial cells during early embryonic development of the rat cortex. J Neurosci 25:9752-9761.
3. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP (2003a) Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 62:195-204.
4. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, Mahadik SP (2003b) Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 53:56-64.
5. Baik JH, Picetti R, Saiardi A, Thiriet G, Dierich A, Depaulis A, Le Meur M, Borrelli E (1995) Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377:424-428.
6. Bamford NS, Zhang H, Schmitz Y, Wu NP, Cepeda C, Levine MS, Schmauss C, Zakharenko SS, Zablow L, SulzerD (2004) Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron 42:653-663.
7. Banaszak L, Winter N, Xu Z, Bernlohr DA, Cowan S, Jones TA (1994) Lipid-binding proteins: a family of fatty acid and retinoid transport proteins [review]. Adv Protein Chem 45:89-151.
8. 2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci 28:5671-5685.
9. Binas B, Danneberg H, McWhir J, Mullins L, Clark AJ (1999) Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization. FASEB J 13:805-812.
10. Bofill-Cardona E, Kudlacek O, Yang Q, Ahorn H, Freissmuth M, Nanoff C (2000) Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch. J Biol Chem 275:32672-32680.
11. Boulay D, Depoortere R, Oblin A, Sanger DJ, Schoemaker H, Perrault G (2000) Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice. Eur J Pharmacol 391:63-73.
12. Cepeda C, Hurst RS, Altemus KL, Flores-Hernández J, Calvert CR, Jokel ES, Grandy DK, Low MJ, Rubinstein M, Ariano MA, Levine MS (2001) Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 85:659-670.
13. Coe NR, Bernlohr DA (1998) Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim Biophys Acta 1391: 287-306.
14. Cools AR (1980) Role of the neostriatal dopaminergic activity in sequencing and selecting behavioural strategies: facilitation of processes involved in selecting the best strategy in a stressful situation. Behav Brain Res 1:361-378.
15. Day M, Wokosin D, Plotkin JL, Tian X, Surmeier DJ (2008) Surmeier DJ. Differential excitability and modulation of striatal medium spiny neuron dendrites. J Neurosci 28:11603-11614.
16. DeBoer P, Heeringa MJ, Abercrombie ED (1996) Spontaneous release of acetylcholine in striatum is preferentially regulated by inhibitory dopamine D2 receptors. Eur J Pharmacol 317:257-262.
17. de Souza IE, Meredith GE (1999) NMDA receptor blockade attenuates the haloperidol induction of Fos protein in the dorsal but not the ventral striatum. Synapse 32:243-253.
18. 2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 37:287-294.
19. Dubé L, Smith AD, Bolam JP (1988) Identification of synaptic terminals of thalamic or cortical origin in contact with distinct medium-size spiny neurons in the rat neostriatum. J Comp Neurol 267:455-471.
20. Fisher RS, Levine MS, Sibley DR, Ariano MA (1994) D2 dopamine receptor protein location: Golgi impregnation-gold toned and ultrastructural analysis of the rat neostriatum. J Neurosci Res 38:551-564.
21. Fujiyama F, Furuta T, Kaneko T (2001) Immunocytochemical localization of candidates for vesicular glutamate transporters in the rat cerebral cortex. J Comp Neurol 435:379-387.
22. 2+/calmodulin-dependent protein kinase II in rat brain and various tissues. J Neurochem 51:1070-1078.
23. Glatz JF, van der Vusse GJ (1996) Cellular fatty acid-binding proteins: their function and physiological significance [review]. Prog Lipid Res 35:243-282.
24. Guyenet PG, Javory AF, Beaujouan JC, Rossier BJ, Glowinski J (1975) Effects of dopaminergic receptor agonists and antagonists on the activity of the neo-striatal cholinergic system. Brain Res 84:227-244.
25. Han F, Shioda N, Moriguchi S, Qin ZH, Fukunaga K (2008) Downregulation of glutamate transporters is associated with elevation in extracellular glutamate concentration following rat microsphere embolism. Neurosci Lett 430:275-280.
26. Hanhoff T, Lücke C, Spener F (2002) Insights into binding of fatty acids by fatty acid binding proteins. Mol Cell Biochem 239:45-54.
27. Holt DJ, Graybiel AM, Saper CB (1997) Neurochemical architecture of the human striatum. J Comp Neurol 384:1-25.
28. Horrocks LA, Yeo YK (1999) Health benefits of docosahexaenoic acid (DHA). Pharmacol Res 40:211-225.
29. Ikarashi Y, Yuzurihara M, Takahashi A, Ishimaru H, Shiobara T, Maruyama Y (1998) Direct regulation of acetylcholine release by N-methyl- D-aspartic acid receptors in rat striatum. Brain Res 795:215-220.
30. Kabbani N, Levenson R (2007) A proteomic approach to receptor signaling: molecular mechanisms and therapeutic implications derived from discovery of the dopamine D2 receptor signalplex [review]. Eur J Pharmacol 572:83-93.
31. Kanterman RY, Mahan LC, Briley EM, Monsma FJ Jr, Sibley DR, Axelrod J, Felder CC (1991) Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Mol Pharmacol 39:364-369.
32. Karler R, Calder LD, Chaudhry IA, Turkanis SA (1989) Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci 45:599-606.
33. Khan ZU, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic PS (1998) Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci U S A 95:7731-7736.
34. Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, Yoshimoto T, Guo J, Yamashima T (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56:159-164.
35. Liu XY, Chu XP, Mao LM, Wang M, Lan HX, LiMH,Zhang GC, Parelkar NK, Fibuch EE, Haines M, Neve KA, Liu F, Xiong ZG, Wang JQ (2006) Modulation of D2R-NR2B interactions in response to cocaine. Neuron 52:897-909.
36. Liu Y, Buck DC, Macey TA, Lan H, Neve KA (2007) Evidence that calmodulin binding to the dopamine D2 receptor enhances receptor signaling. J Recept Signal Transduct Res 27:47-65.
37. Maura G, Giardi A, Raiteri M (1988) Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. J Pharmacol Exp Ther 247:680-684.
38. Mellor JE, Laugharne JD, Peet M (1995) Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophr Res 18:85-86.
39. Moo-Puc RE, Góngora-Alfaro JL, Alvarez-Cervera FJ, Pineda JC, Arankowsky-Sandoval G, Heredia-López F (2003) Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. Neuropharmacology 45:493-503.
40. Murphy EJ, Owada Y, Kitanaka N, Kondo H, Glatz JF (2005) Brain arachidonic acid incorporation is decreased in heart fatty acid binding protein gene-ablated mice. Biochemistry 44:6350-6360.
41. Narushima M, Uchigashima M, Hashimoto K, Watanabe M, KanoM (2006) Depolarization-induced suppression of inhibition mediated by endocannabinoids at synapses from fast-spiking interneurons to medium spiny neurons in the striatum. Eur J Neurosci 24:2246-2252.
42. Noble EP (2003) D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 116B:103-125.
43. Owada Y, Yoshimoto T, Kondo H (1996) Spatio-temporally differential expression of genes for three members of fatty acid-binding proteins in developing and mature rat brains. J Chem Neuroanat 12:113-122.
44. Owada Y, Abdelwahab SA, Kitanaka N, Sakagami H, Takano H, Sugitani Y, Sugawara M, Kawashima H, Kiso Y, Mobarakeh JI, Yanai K, Kaneko K, Sasaki H, Kato H, Saino-Saito S, Matsumoto N, Akaike N, Noda T, Kondo H (2006) Altered emotional behavioral responses in mice lacking brain-type fatty acid-binding protein gene. Eur J Neurosci 24:175-187.
45. Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates. San Diego: Academic.
46. Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G (1995) Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 29:227-232.
47. Pickel VM, Beckley SC, Joh TH, Reis DJ (1981) Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum. Brain Res 225:373-385.
48. Piomelli D, Pilon C, Giros B, Sokoloff P, Martres MP, Schwartz JC (1991) Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature 353:164-167.
49. 2-like dopamine receptors reduces synaptic inputs to striatal cholinergic interneurons. J Neurosci 20:RC69.
50. Scatton B (1982) Further evidence for the involvement of D2, but not D1 dopamine receptors in dopaminergic control of striatal cholinergic transmission. Life Sci 31:2883-2890.
51. Scatton B, Lehmann J (1982) N-methyl-D-aspartate-type receptors mediate striatal 3H-acetylcholine release evoked by excitatory amino acids. Nature 297:422-424.
52. Schinelli S, Paolillo M, Corona GL (1994) Opposing actions of D1-and D2-dopamine receptors on arachidonic acid release and cyclic AMP production in striatal neurons. J Neurochem 62:944-949.
53. 2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci 14:88-106.
54. Shioda N, Han F, Moriguchi S, Fukunaga K (2007) Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. J Neurochem 102:1506-1517.
55. Smith FD, Oxford GS, Milgram SL (1999) Association of the D2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1- interacting protein. J Biol Chem 274:19894-19900.
56. Stewart J, Druhan JP (1993) Development of both conditioning and sensitization of the behavioral activating effects of amphetamine is blocked by the non-competitive NMDA receptor antagonist, MK-801. Psychopharmacology (Berl) 110:125-132.
57. Takeuchi Y, Fukunaga K (2003a) Differential subcellular localization of two dopamine D2 receptor isoforms in transfected NG108-15 cells. J Neurochem 85:1064-1074.
58. Takeuchi Y, Fukunaga K (2003b) Differential regulation of NF-kappaB, SRE and CRE by dopamine D1 and D2 receptors in transfected NG108-15 cells. J Neurochem 85:729-739.
59. Takeuchi Y, Fukunaga K (2004) Dopamine D2 receptor activates extracellular signal-regulated kinase through the specific region in the third cytoplasmic loop. J Neurochem 89:1498-1507.
60. Usiello A, Baik JH, Rougé-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E (2000) Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408:199-203.
61. Veerkamp JH, Maatman RG (1995) Cytoplasmic fatty acid-binding proteins: their structure and genes [review]. Prog Lipid Res 34:17-52.
62. Wada-Isoe K, Imamura K, Kitamaya M, Kowa H, Nakashima K (2008) Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J Neurol Sci 266:20-24.
63. Wang Y, Xu R, Sasaoka T, Tonegawa S, Kung MP, Sankoorikal EB (2000) Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J Neurosci 20:8305-8314.
64. Watanabe A, Toyota T, Owada Y, Hayashi T, Iwayama Y, Matsumata M, Ishitsuka Y, Nakaya A, Maekawa M, Ohnishi T, Arai R, Sakurai K, Yamada K, Kondo H, Hashimoto K, Osumi N, Yoshikawa T (2007) Fabp7 maps to a quantitative trait locus for a schizophrenia endophenotype. PLoS Biol 5:e297.
65. Welter M, Vallone D, Samad TA, Meziane H, Usiello A, Borrelli E (2007) Absence of dopamine D2 receptors unmasks an inhibitory control over the brain circuitries activated by cocaine. Proc Natl Acad SciUS A104:6840-6845.
66. 2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein kinase C-insensitive pathway. J Neurophysiol 77:1003-1015.